SCHEMBL1894359

SCHEMBL1894359

CCCCC/C=C\C[C@@H](O)/C=C/c1cccc(C[C@@H](O)CCCCO)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 7/20 1.00
ALDH1A1 P00352 3/20 1.00
NFKB1 P19838 2/20 1.00
MTOR P42345 1/20 1.00
PMP22 Q01453 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
ALOX15 P16050 1/20 1.00
KDM4E B2RXH2 1/20 1.00
PLIN1 O60240 1/20 1.00
GAA P10253 1/20 1.00
MAPT P10636 1/20 1.00
MAPK1 P28482 1/20 1.00
PLIN5 Q00G26 1/20 1.00
ABHD5 Q8WTS1 1/20 1.00
FFAR1 O14842 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
FAAH O00519 5/20 0.37
LTB4R2 Q9NPC1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10511272 1.00 LTB4R (1.00) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL29462291 1.00 LTB4R (1.00) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL10511276 1.00 LTB4R (1.00) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9237815 1.00 LTB4R (1.00) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9235257 0.88 LTB4R (0.79) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9235263 0.88 LTB4R (0.79) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9239472 0.88 LTB4R (0.79) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9237509 0.86 LTB4R (0.75) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9232710 0.86 LTB4R (0.75) LTB4RALDH1A1NFKB1MTORPMP22
SCHEMBL9235542 0.86 LTB4R (0.75) LTB4RALDH1A1NFKB1MTORPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170333516-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION JUNTENDO EDUCATIONAL FOUNDATION (JP) 2017-11-23 US claimed
EP-3215146-B1 BLT2 AGONISTS FOR THE TREATMENT OF PAIN FRAUNHOFER GES FORSCHUNG (DE) 2021-02-17 EP disclosed
US-10849954-B2 Preventive or therapeutic agent for age-related macular degeneration JUNTENDO EDUCATIONAL FOUNDATION (JP) 2020-12-01 US disclosed
US-20190216790-A1 Methods for Treating Pruritis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-07-18 US disclosed
US-20170333516-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION JUNTENDO EDUCATIONAL FOUNDATION (JP) 2017-11-23 US disclosed
US-20170281575-A1 BLT2 AGONISTS FOR THE TREATMENT OF PAIN Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2017-10-05 US disclosed
EP-3017813-A1 BLT2 agonists for the treatment of pain Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2016-05-11 EP disclosed
US-20110105959-A1 Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway ACCELALOX, INC. (US) 2011-05-05 US disclosed
US-20090280153-A1 electrical devices, anti-scarring agents, and therapeutic compositions ANGIOTECH INTERNATIONAL AG (CH) 2009-11-12 US disclosed
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS ANGIOTECH PHARMACEUTICALS, INC (CA) 2009-09-10 US disclosed
EP-1978930-A2 SUTURES AND ANTI-SCARRING AGENTS Angiotech Pharmaceuticals, Inc. (CA) 2008-10-15 EP disclosed
WO-2007089878-A2 SUTURES AND ANTI-SCARRING AGENTS ANGIOTECH PHARMACEUTICALS, INC. (CA) 2007-08-09 WO disclosed
WO-2006121522-A2 IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS ANGIOTECH INTERNATIONAL AG (CH) 2006-11-16 WO disclosed
WO-2006121518-A2 ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS ANGIOTECH INTERNATIONAL AG (CH) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10849954-B2 Preventive or therapeutic agent for age-related macular degeneration LTB4R, LTA4H, LTB4R2 LTB4R 1/4885ALDH1A1 486/4885NFKB1 844/4885
US-20190216790-A1 Methods for Treating Pruritis ITCH, CYSLTR2, CYSLTR1 LTB4R 8/4885ALDH1A1 2690/4885NFKB1 1631/4885
US-20170333516-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION LTB4R, LTA4H, LTB4R2 LTB4R 1/4885ALDH1A1 486/4885NFKB1 844/4885
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS COL1A1, COL2A1, COL14A1 LTB4R 374/4885ALDH1A1 2866/4885NFKB1 722/4885
US-20090280153-A1 electrical devices, anti-scarring agents, and therapeutic compositions GAP43, TNNC1, GJB2 LTB4R 352/4885ALDH1A1 1855/4885NFKB1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.